SCHEMBL2303635

SCHEMBL2303635

CCOC(=O)C1CCN(c2ccc(C(=O)Nc3ccc(-c4ccccc4F)c(C)c3)cn2)CC1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.51
DGAT1 O75907 6/20 0.51
PTPN11 Q06124 1/20 0.48
ADORA3 P0DMS8 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
KCNQ3 O43525 1/20 0.45
KCNQ2 O43526 1/20 0.45
LMNA P02545 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HDAC3 O15379 1/20 0.44
HDAC2 Q92769 1/20 0.44
KMT2A Q03164 1/20 0.44
P2RY12 Q9H244 1/20 0.43
MCHR1 Q99705 1/20 0.43
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2302353 0.94 USP30 (0.51) USP30DGAT1PTPN11ADORA3L3MBTL1
SCHEMBL2302301 0.89 DGAT1 (0.57) USP30DGAT1PTPN11ADORA3LMNA
SCHEMBL3315908 0.84 DGAT1 (0.57) USP30DGAT1PTPN11ADORA3LMNA
SCHEMBL2304990 0.84 USP30 (0.56) USP30DGAT1PTPN11L3MBTL1TDP1
SCHEMBL2302625 0.84 DGAT1 (0.55) USP30DGAT1L3MBTL1TDP1
SCHEMBL2302615 0.83 ADORA3 (0.52) USP30DGAT1PTPN11ADORA3KMT2A
SCHEMBL2306069 0.83 DGAT1 (0.51) USP30DGAT1PTPN11ADORA3L3MBTL1
SCHEMBL2301869 0.83 DGAT1 (0.52) USP30DGAT1ADORA3L3MBTL1TDP1
SCHEMBL2304947 0.82 USP30 (0.56) USP30DGAT1PTPN11L3MBTL1LMNA
SCHEMBL3309358 0.79 DGAT1 (0.55) DGAT1L3MBTL1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350311-B1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS MADRIGAL PHARMACEUTICALS INC (US) 2013-12-25 EP disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 US disclosed
EP-2350311-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2011-08-03 EP disclosed
WO-2010056506-A1 DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed
WO-2010056506-A1 DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2010-05-20 WO disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, MOGAT2 USP30 2018/4885DGAT1 2/4885PTPN11 3435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.